Bioscience Vaccines, Inc. is currently pursuing two areas of technology:  

• Development of a novel vaccine adjuvant and companion products targeting infectious diseases
  

• Exploration of prevention and immunotherapeutic treatments for cancer using tissue vaccines

BVI’s novel adjuvant enhances the efficacy of vaccines by stimulating the body’s own protective (immune) response to be more powerful. As the vaccine market approaches $22 billion by 2015, adjuvants will serve as an important factor in the development of new vaccines, and BVI’s adjuvant is positioned to meet those needs.

 

Tissue vaccines are a new and unique approach to cancer treatment and prevention. By using material harvested from tumors, they are able to capture a multitude of targets for the immune system to attack. Vaccines created from xenogenic materials stimulate a particularly robust immune response, similar to the vigorous immune response seen when organ transplants are attempted between species.  Harnessing this natural response, tissue vaccines such as BVI’s can be used to reduce or even eliminate tumors.

 

Click here for Infectious Disease Data

Click here for Market Opportunity Information

 

References:

Use of an Extracellular Matrix Material as a Vaccine Carrier and Adjuvant

Prevention of de novo Prostate Cancer by Immunization with Tumor-Derived Vaccines

Inhibition of Prostate Cancer Metastasis by Administration of a Tissue Vaccine

Immunization with a Tissue Vaccine Enhances the Effect of Irradiation on Prostate Tumor

Prevention of Human PC-346C Prostate Cancer Growth in Mice by a Xenogeneic Tissue Vaccine